Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma
Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma
The Objective was to Develop a Cost-Effectiveness study that compares Ciclesonide and
 Beclomethasone in pediatric asthma control.
Cost-effectiveness study, of cohorts, observational, analytic, prospective, from health
 institution perspective. Based on published data related to percentage of patients free of
 crisis for both molecules, it was estimated that the sample size to detect significant
 differences between the two alternatives was 20 patients per alternative. Medical records of
 94 patients with diagnosis of uncontrolled asthma were included, aged between 6 and 15 years,
 47 received Beclomethasone randomly, and 47 received Ciclesonide randomly, treatment
 physician was blind related to this assignation, both cohorts were followed for 6 months, and
 primary effectiveness variable was defined as number of patients free of crisis with each
 alternative. Cost generating variables were defined as medication use, and hospital stay.
 Decision analysis was based on a decision tree.
Inclusion Criteria:

 -  Patients with uncontrolled asthma diagnosis

 -  Patients with only one controller medication

 Exclusion Criteria:

 -  Patients without lung infection

 -  Patients without antibiotic use